HOME >> MEDICINE >> NEWS
Premature use of stem cell therapy could put patients at risk

The premature use of stem cell therapy could put many patients at risk of viral or prion diseases unless appropriate safety systems are in place, warn experts in this week's BMJ.

The use of human embryonic stem cells has been hailed as the next major step in the battle against serious degenerative disorders, such as diabetes and Parkinson's disease. But is this just hype, and how much hope should patients invest in this technology? These are some of the issues that will be discussed at a public debate in London next week.

The lessons of premature application of gene therapy, the devastation caused by HIV transmission to people with haemophilia, and the crisis caused by bovine spongiform encephalopathy (BSE) should all be learning opportunities, say the authors.

Expansion of stem cell cultures could allow a single stem cell line to be used for many hundreds, if not thousands of patients, exponentially amplifying the potential risk of disease transmission from a single infected donor.

Change is on the way, however. By April 2006, all laboratories for in vitro fertilisation and laboratories for producing cell lines with therapeutic intent will have to comply with the EU Directive on tissues and cells. This will cover selection of donors, testing, and procurement of the starting material for cell lines, tracking cells from donor to recipient, and reporting of adverse events.

The authors suggest a novel alternative approach whereby the expanded stem cell lines themselves could be tested for a variety of pathogens before they are released. This would provide an additional safety step and provide an alternative in the armamentarium for testing these important donations for transplantation.

The drive to be the first to produce cell lines for therapy without appropriate controls could compromise safety for recipients and could lead this technology into the realms of quackery, say the authors. Such fears are already being realis
'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
19-May-2005


Page: 1 2

Related medicine news :

1. Premature or low birthweight babies at significantly increased risk of hyperactivity disorder
2. Premature baby ventilation trial cleared of causing long-term harm to participants
3. Premature babies and SIDS: Doctors should make special effort to talk to parents About Risk
4. Chemotherapy with bevacizumab increases risk of blood clots in arteries
5. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
6. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
7. Hormone therapy offers new hope for ovarian cancer patients
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
10. Chemotherapy may enhance the effectiveness of brain tumor vaccines
11. Brain-boosting pill alleviates post-chemotherapy fogginess

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Premature use stem cell therapy could put patients risk

(Date:3/29/2015)... The Claudia Cohen Research Foundation and ... that Dr. Beth Y. Karlan has been selected as ... Prize for Outstanding Gynecologic Researcher. The $50,000 prize is ... Annual Meeting on Women's Cancer in Chicago. , Dr. ... at the Samuel Oschin Comprehensive Cancer Institute and Director ...
(Date:3/29/2015)... 2015 Final Cut Pro X ... Pixel Film Studios, entitled TranSports. , “TranSports is ... Final Cut Pro X,” said Christiana Austin, CEO of ... needed to effortlessly transition using this cool sports transition ... and uniquely styled transition pack for Final Cut Pro ...
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared a ... during the Easter Holidays from today until April 6th. ... Fools’ Day. , As the winter fades and spring ... Festival, with religious origins to countries in Europe and ... The best wig provider, UniWigs, would like to offer ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for multiple ... injuries, according to new research released today at the American ... , “Our findings indicate that a 10 inch increase in ... a history of injury, a 10 mile per hour increase ... a history of injury, and playing for more than one ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2
(Date:3/27/2015)... 27, 2015 As of February, InControl ... devices for women. "Shipping thousands of ... part is the hundreds of letters, emails and ... have been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution ...
(Date:3/27/2015)... , March 27, 2015  RXi Pharmaceuticals ... MirImmune LLC, today announced that they have ... RXi,s novel and proprietary sd-rxRNA® technology for ... The collaboration has the potential to result ... cancer treatments that could be a significant ...
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
Cached News: